Đang chuẩn bị liên kết để tải về tài liệu:
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: A meta-analysis

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Cisplatin-based treatment has been considered the standard treatment regimen of HNSCC. Cetuximab is an emerging target therapy that has potential therapeutic benefits over cisplatin. Nevertheless, curative effects of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradiotherapy (BRT) are still controversial. |

TÀI LIỆU LIÊN QUAN

Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy

Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: A multicenter study

Clinicopathological variables influencing overall survival, recurrence and postrecurrence survival in resected stage I nonsmall-cell lung cancer

Significant association of long non-coding RNAs HOTAIR genetic polymorphisms with cancer recurrence and patient survival in patients with uterine cervical cancer

Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis

Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients

KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma

New method for determining breast cancer recurrence-free survival using routinely collected real-world health data

The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: A food-based multicentre randomized controlled trial